Comments
Drugmaker Cipla clocked a net profit of ₹407 crore for the three months ended September 30, 2015.
The financial performance in the quarter under review was not comparable to the corresponding period in the previous year, the company said, since it included the results of Cipla’s subsidiaries as well.
The company’s total income from sales for the quarter stood at ₹3,073 crore.
The results for the current period included a one-off revenue from the US market, it said. Over 60 per cent of the company’s revenues come from outside India.
Giving details of its performance, the company said that its domestic sales grew by 0.9 per cent to ₹1,262 crore in the period under review.
The exports of finished drugs increased by 51 per cent to ₹1,874 crore during Q2 FY15-16, the company said.
The export of active pharmaceutical ingredients (API) increased by 61 per cent to ₹226 crore during three months under review, it added.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.